Schlotter Claus M, Vogt Ulf, Allgayer Heike, Brandt Burkhard
Department of Obstetrics and Gynecology, Breast Centre Klinikum Lüdenscheid, Academic Teaching Hospital of the University Bonn, Luedenscheid, Paulmannshoeher Str, 14 - 58515 Luedenscheid Germany.
Breast Cancer Res. 2008;10(4):211. doi: 10.1186/bcr2112. Epub 2008 Jul 24.
Targeting the oestrogen receptor, HER2 (human epidermal growth factor receptor 2) and vascular endothelial growth factor has markedly improved breast cancer therapy. New targeted therapeutic approaches to induction of apoptosis or inhibition of anti-apoptosis, cell cycle progression, signal transduction and angiogenesis are described. The molecular pathways and their inhibitory or repair mechanisms are discussed in the preclinical and clinical settings.
针对雌激素受体、HER2(人表皮生长因子受体2)和血管内皮生长因子的治疗显著改善了乳腺癌治疗。本文描述了诱导细胞凋亡或抑制抗凋亡、细胞周期进程、信号转导和血管生成的新的靶向治疗方法。在临床前和临床环境中讨论了分子途径及其抑制或修复机制。